About Allecra
Allecra is a company based in Weil Am Rhein (Germany) founded in 2013. Allecra has raised $44.44 million across 2 funding rounds from investors including Edmond de Rothschild, Forbion and EMBL Ventures. Allecra operates in a competitive market with competitors including Paratek Pharma, Spero Therapeutics, Cempra, Bugworks Research and Locus Biosciences, among others.
- Headquarter Weil Am Rhein, Germany
- SectorsHealthcare
- Website allecra.com
- Social LinkedIn
- Legal Name Allecra Therapeutics Gmbh
- Total Equity Funding$44.44M (USD)
in 2 rounds
- Latest Funding Round$24.75M (USD), Series B
Jun 2016
- InvestorsEdmond de Rothschild
& 3 more
Funding Insights of Allecra
Allecra has successfully raised a total of $44.44M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $24.75 million completed in June 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $44.44M
- Total Rounds 2
- Last Round Series B — $24.75M
- First Round $19.69M
(Apr 2013)
- Investors Count 4
All 2 funding rounds of Allecra with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2016 | $24.75M | Series B | – | Delos Capital Partners | |
| Apr 2013 | $19.69M | Series A | – | Forbion, Edmond de Rothschild |
4 investors in total: 4 institutional.
Investors in Allecra
Allecra has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include Edmond de Rothschild, Forbion and EMBL Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on lifescience and healthcare sectors | – | forbion.com | Naarden, Netherlands | |
Diversified asset management, corporate advisory, and private equity firm focused on multiple sectors | 1953 | edmond-de-rothschild.com | Paris, France | |
Life science companies are supported through strategic investments. | – | embl-ventures.com | Heidelberg, Germany | |
Venture capital investments are directed toward therapeutics and medtech startups. | – | deloscapital.com | Hong Kong, China |
Investor details for Allecra
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Allecra
3 people are tracked at Allecra (2 in leadership, 1 in team).
| Name | Role | Group |
|---|---|---|
Andreas Kranzusch | Managing Director | Leadership |
Velicitat Patrick | Chief Medical Officer | Leadership |
Divya Choudhary | Global Clinical Project Manager | Team |
Complete people profiles for Allecra
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Allecra
3 dated milestones of Allecra across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Allecra is founded.
- Funding First funding round of $19.7M.
- Funding Latest funding round, Series B, of $24.7M.
Competitors of Allecra
Allecra operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Paratek Pharma, Spero Therapeutics, Cempra, Bugworks Research and Locus Biosciences, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| paratekpharma.com | 1996 | Boston, United States | $96.48M | 205 | Therapeutics for antimicrobial resistant infections are developed. | |
| sperotherapeutics.com | 2013 | Cambridge, United States | $114.7M | 46 | Therapeutics for drug-resistant bacterial infections are developed. | |
| cempra.com | 2006 | Chapel Hill, United States | $149.5M | 78 | Clinical-stage pharmaceutical company focused on developing antibacterials | |
| bugworksresearch.com | 2014 | Saratoga, United States | $42.89M | 31 | Drugs for antibiotic-resistant infections and cancer are developed. | |
| locus-bio.com | 2015 | Raleigh, United States | $67.33M | 74 | Developer of therapeutics for infectious disease and inflammatory indications | |
| aphage.com | 2016 | Bethesda, United States | $107.87M | 78 | Therapies for multi-drug resistant infections are developed using bacteriophages. | |
| iterumtx.com | 2015 | Dublin, Ireland | $78.1M | – | Developer of antibiotics for MDR infections | |
| vedantabio.com | 2010 | Cambridge, United States | $350.49M | 71 | Therapeutics for infectious and autoimmune diseases are developed. | |
| bioversys.com | 2008 | Basel, Switzerland | $62.46M | – | Antibacterial therapeutics for multi-drug resistant infections are developed. | |
| melinta.com | 2000 | Morristown, United States | $186M | 290 | Developer of bacterial ribosome-targeting drugs for MDR infections |
Detailed competitors of Allecra
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Allecra
The website of Allecra (allecra.com) receives about 1.3K visits a month.
- Monthly visits1.3K
▼ 22.5% vs previous month
Latest news on Allecra
Complete news archive for Allecra
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Allecra
10 companies that operate in the same segment as Allecra (Infectious Diseases), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 | |
Clinical diagnostics and drug discovery for immune diseases are provided. | 2009 | Seattle, Washington, United States | USD 419.15 M | USD 276.98 M | 619 | |
Vaccines for infectious diseases are developed using cell-free protein synthesis. | 2013 | Foster City, California, United States | USD 347 M | – | 414 | |
Portable PCR diagnostics for infectious diseases are developed. | 2010 | San Jose, California, United States | USD 386.33 M | – | – | |
Developing glucan synthase inhibitors for the treatment of fungal infections. | 1999 | Jersey City, New Jersey, United States | USD 62.65 M | USD 20.6 M | 28 | |
Sherlock Biosciences is focused on molecular diagnostics development. | 2019 | Watertown, United States | USD 111 M | – | 33 | |
Provider of diagnostic solutions for systemic infections | 2016 | San Francisco, California, United States | USD 191.47 M | – | 54 | |
Developer of novel protein-based therapeutics using machine learning and biological engineering | 2018 | Somerville, Massachusetts, United States | USD 693 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Allecra
Allecra was founded in 2013.
Allecra is headquartered in Weil Am Rhein, Germany. It is registered at Weil Am Rhein, Baden-wurttemberg, Germany.
Allecra is a funded company, having raised a total of $44.44M across 2 funding rounds to date. The company's 1st funding round was a Series A of $19.69M, raised on Apr 2013.
Allecra was founded in 2013 and operates in the biotechnology sector, where antibiotics are developed to address multi-drug-resistant bacterial infections. Two product candidates, cefepime and enmetazobactam, have been created specifically for Gram-negative infections, such as complicated urinary tract infections. Focus is placed on combating antibiotic resistance through targeted therapeutic advancements.
Allecra's top competitors include Spero Therapeutics, Melinta Therapeutics and Vedanta Biosciences.
Allecra has 4 investors. Key investors include Edmond de Rothschild, Forbion, EMBL Ventures, and Delos Capital Partners.
Allecra operates through Allecra Therapeutics Gmbh.